

Paradigm CFO resigns and the Board appoints interim CFO.

Paradigm Biopharmaceuticals Ltd (ASX: PAR, “Paradigm” or “the Company”), a late-stage drug development company focused on delivering new therapies to address unmet medical needs, advises that Ms Abby Macnish Niven has been appointed Interim Chief Financial Officer (**CFO**) following the resignation of Mr Justin Cahill from the role.

Paradigm Managing Director, Paul Rennie, said: “On behalf of all Paradigm employees and Board members, I would like to thank Justin for the contribution he has made to Paradigm over the past two and a half years. Justin has played an important role in our business in stewarding the ongoing strong financial position of Paradigm, and the Board and I wish Justin all the best in his new role. We wish him well in the future.”

Abby Macnish Niven, the Company’s current Company Secretary, has been appointed Interim CFO, effective from Friday 3 March 2023. She is the part-time CFO and Company Secretary for two other ASX listed companies. She has a bachelor’s degree in science and commerce from the University of Western Australia and is a Chartered Financial Analyst® charter-holder.

Justin is available to support the team and ensure an orderly CFO transition.

-Ends-

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. (ASX: PAR) is a late-stage drug development company driven by a purpose to improve patients' health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm's current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (**iPPS**) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).

Forward Looking Statements

This Company announcement contains forward-looking statements, including statements regarding anticipated commencement dates or completions dates of preclinical or clinical trials, regulatory developments and regulatory approval. These forward-looking statements are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this presentation. Readers are cautioned not to put undue reliance on forward-looking statements.

Authorised for release by the Paradigm Board of Directors.

To learn more please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd.

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com